

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay

Caterina Fumagalli^{1,2}, Ilaria Betella³, Alberto Ranghiero¹, Elena Guerini-Rocco^{1,4}, Giulio Bonaldo³, Alessandra Rappa¹, Davide Vacirca¹, Nicoletta Colombo^{5,6}, Massimo Barberis¹

¹ Clinical Unit of Oncogenomics, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; ² Division of Pathology, Department of Diagnostic Services, Azienda Socio Sanitaria Territoriale (ASST) Valle Olona, Gallarate, Italy; ³ Division of Gynecologic Surgery, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; ⁴ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; ⁵ Division of Gynecologic Oncology, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; ⁶ School of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Milan, Italy

Summary

Background. Homologous recombination repair (HRR) is the main mechanism of repair of DNA double-strand breaks. Its deficiency (HRD) is a common feature of epithelial ovarian cancers (EOCs). BRCA1/2 mutations and/or other aberrations in genes of HRR are well known causes of HRD and genomic instability. Poly ADP-ribose polymerase inhibitors (PARPi) have revolutionized the management of BRCA mutant EOCs and demonstrated activity in HRD tumor cells. Determining HRD status can provide informations on the magnitude of benefit for PARPi therapy. Myriad MyChoice CDx is a next generation sequencing-based in vitro diagnostic test that assesses the Genomic Instability Score (GIS) which is an algorithmic measurement of loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions using DNA isolated from formalin-fixed paraffin embedded tumor tissue specimens. However Myriad MyChoice CDx, is a centrally performed and costly assay, with no reimbursement scheduled, at least in Italy.

Methods. In this report, we described our experience in performing the HRD Focus AmoyDx (Amoy Diagnostics Ltd, Xiamen, Fujian, China) on the same samples of EOCs evaluated with Myriad MyChoiceCDx assay.

Results. The overall percent agreement between AmoyDx and Myriad was 87.8% (65 of 74 tumors tested). All the 36 AmoyDx negative cases were confirmed to be negative by Myriad (negative predictive value, 100%).

Conclusions. The concordance of the results with the gold standard Myriad MyChoice CDx assay suggest the feasibility and reliability of HRD testing in diagnostic laboratories with high-throughput NGS platforms and qualified personnel.

Key words: ovarian cancer, homologous recombination deficiency, genomic scar, HRD

Introduction

Ovarian cancer represents the 3% of all cancers occurring in female and is the sixth cause of cancer-related death in women worldwide, globally accounting for 294,000 new cases and 198,000 deaths per year ¹ and 5000 new cases and more than 3000 deaths per year in Italy ². The high grade serous ovarian carcinoma (HGSO) is the most frequent (about

Received: July 19, 2022
Accepted: July 20, 2022

Correspondence

Massimo Barberis
Clinical Unit of Oncogenomics, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 20141, Milan, Italy
E-mail: Massimo.barberis@ieo.it

How to cite this article: Fumagalli C, Betella I, Ranghiero A, et al. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. *Pathologica* 2022;114:17-23. <https://doi.org/10.32074/1591-951X-791>

© Copyright by Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology



OPEN ACCESS

This is an open access journal distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license: the work can be used by mentioning the author and the license, but only for non-commercial purposes and only in the original version. For further information: <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

70%) and lethal ovarian cancer histotype. The large majority of HGSOc are diagnosed in advanced stage (FIGO stage III-IV) and despite cytoreductive surgery associated with platinum-based chemotherapy, will relapse within two years³. The introduction of PARP inhibitors (PARPi) in first-line therapeutic regimens of women with platinum-sensitive ovarian cancers has dramatically changed clinical outcomes, both in terms of progression free and overall survival⁴⁻⁷. Except for BRCA1/2 mutated cancers, which present the higher magnitude of clinical benefit for PARPi, this class of drugs show great efficacy also in BRCA wild type tumors with homologous recombination repair deficiency (HRD)⁶⁻⁸. Clinically meaningful improvements reported in recent trials^{6,7} have led to the approval of PARPis alone or in combination with antiangiogenetic therapy for the maintenance treatment of patients with HRD-positive advanced ovarian cancer (Food and Drug Administration⁹ and European Medicines Agency¹⁰ in 2020, and Agenzia Italiana del Farmaco¹¹ in 2022). As recently reported in European expert consensus recommendations¹², BRCA1/2 tumor assessment should be associated with the evaluation of homologous recombination repair (HRR) status, as a pivotal step to extend effective PARPi treatment to the largest number of patients, considering that about 20-25% of HGSOcs harbor BRCA1/2 alterations and more than 50% are characterized by HRD¹³.

The challenging topic is how to evaluate HRD in routine clinical practice. In the clinical trials PAOLA1⁷, PRIMA⁶ and VELIA⁸, HRD assessment was performed with the FDA approved myChoiceCDx (Myriad) assay, which considered *BRCA1* and *BRCA2* status and HRD-induced genomic scar. However, this assay is centrally performed, costly and not reimbursed by the National Healthcare System. Next generation sequencing panels evaluating HRR genes, beyond BRCA1/2, may improve the detection rate of tumour with HRD by only 5-6%¹³. Commercial assays applicable in diagnostic laboratories that screen for HRR genes along with genomic scar have been recently developed¹⁴.

In this study, we report our first experience with in-house HRD testing, using the HRD Focus panel (AmoyDx), which evaluates both BRCA1/2 status and genomic instability. We performed a double-blind evaluation of HRD status in a consecutive series of high grade epithelial ovarian cancers that were analyzed in our laboratory with HRD Focus panel and sent to Myriad for MyChoiceCDx testing. We aimed: i) to evaluate the feasibility of HRD testing with an assay applicable in a diagnostic clinical setting; ii) to compare HRD assessment obtained with the HRD Focus panel and the reference assay myChoiceCDx.

Methods

STUDY COHORT

This single-institution study obtained specific Review Board approval (UID 2386). From the institutional electronic database, we selected all patients with high grade serous and endometrioid ovarian cancer treated at the European Institute of Oncology (IEO), Milan, Italy who underwent molecular analysis of HRR deficiency between April 2021 and April 2022. Demographic, clinicopathological and surgical characteristics were abstracted from clinical records. First line therapy indications were considered according with EMA criteria. Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools¹⁵.

HRD TESTING

In-house HRD evaluation was performed with the HRD Focus Assay (CE-IVD) provided by AmoyDx (AmoyDx, Xiamen, China), following the manufacturer's instructions. Briefly, 100 ng of DNA (50 ng minimum yield request) extracted from representative formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks were used for library preparation, and then sequenced on Illumina NextSeq platform. This assay allowed the simultaneous analysis of SNVs and indels in the whole coding regions and exon-intron boundaries of *BRCA1* and *BRCA2*, and estimated a genomic scar score (GSS) based on the analysis of 24,000 SNPs¹⁶. A GGS equal or higher than 50 was indicative of HRD positivity. The bioinformatic algorithm applied for the NGS data analysis was the version 1.1. The same FFPE tumor blocks used for AmoyDx evaluation were sent to Myriad, for performing myChoiceCDx assay. *BRCA1* and *BRCA2* status was evaluated along with HRD assessment, measured by a genomic instability score (GIS) score encompassing measured by loss of heterozygosity, telomeric allelic imbalance) and large-scale state transitions across the entire genome. A GIS equal or higher than 42 was indicative of HRD positivity.

STATISTICAL ANALYSIS

Statistical analysis was carried out using SPSS Statistic 25 software. Chi-Square test with Yates correction and t-test calculators were used for data comparison of categorical variables. p-values < 0.05 were considered statistically significant.

Results

Among the 101 ovarian cancer patients referred to

the Clinical Unit of Oncogenomics for HRD analysis, 6 were excluded from the current analysis as they had already undergone BRCA testing externally and were evaluated with Myriad myChoiceCDx only. The remaining 95 cases reached the minimum tumor cellular content required for AmoyDx (above than 30%) and Myriad (above than 20%) and were included in the present study. The most representative FFPE tumor block was sent to Myriad after section cutting (6 sections 5 µm-thick) for AmoyDxHRD testing (Fig. 1). The clinicopathological characteristics of this population are reported in Table I.

AMOYDX HRD FOCUS PANEL RESULTS

95 cases underwent DNA extraction, obtaining a median concentration of 38.6 ng/µl (range 1.1-99.7 ng/µl). In 84 cases (88.4%) DNA was extracted from surgical specimens, while in 11 cases (11.6%) DNA was extracted from biopsies. 15 of 95 (15.8%) samples, including 5 biopsies and 10 surgical specimens, were not adequate for analysis with AmoyDx HRD Focus panel due to the low DNA yield and were addressed

Table I. Clinico-pathological features of the study population.

Clinico-pathological features	N (%)
Patients	95
Age at diagnosis	
Median (years), range	62 (36-82)
Oncological treatment	
NACT	41 (43.2%)
PCS	54 (56.8%)
Family history for cancer in first and second degree relatives	
Positive	58 (61.1%)
Negative	37 (38.9%)
Histotype	
High grade serous carcinoma (HGSOC)	93 (97.9%)
High grade endometrioid carcinoma (HGEOC)	1 (1.1%)
Malignant mixed Mullerian tumor (MMMT)	1 (1%)
tBRCA status	
BRCA1/2 wt	87 (91.6%)
BRCA1 pathogenic/BRCA2 wt	3 (3.2%)
BRCA1 wt/BRCA2 pathogenic	2 (2.1%)
NA	3 (3.2%)

NACT = neoadjuvant chemotherapy, PCS = primary cytoreductive surgery, tBRCA = tumor BRCA, wt = wild type.




Figure 1. Study design.

*Next Generation sequencing panel: “Oncomine BRCA Research Assay” (ThermoFisher Scientific, Waltham, Massachusetts, USA). HGSOC: High grade serous carcinoma; HGEOC: High grade endometrioid carcinoma; MMMT: Malignant Mixed Mullerian tumor.

to tumor BRCA test assessment only, as previously reported¹⁷. The remaining 80 (84.2%) samples were subjected to HRD testing, giving a result in all the cas-

Table II. AmoyDX HRD testing results according to clinico-pathological characteristics.

Clinico-pathological feature		HRD Positive (n = 38)	HRD Negative (n = 42)	p value
Age at diagnosis median (range)		59.5 (36-79)	64 (43-82)	0.03*
Histotype				
	HGSOC	38 (100%)	40 (95.2%)	
	HGEOC	0	1 (2.4%)	0.99
	MMMT	0	1 (2.4%)	
Family history				
	Positive	26 (68.4%)	21 (50%)	0.09
	Negative	12 (31.6%)	21 (50%)	
tBRCA status				
	Positive	4 (10.5%)	1 (2.4%)	0.13
	Negative	34 (89.5%)	41 (97.6%)	

* p value statistically significant.

HGSOC: High grade serous carcinoma; HGEOC: High grade endometrioid carcinoma; MMT: Malignant mixed Mullerian tumor; tBRCA = tumor BRCA.

Table III. HRD status comparison between AmoyDX and Myriad results.

HRD Focus panel	AmoyDX	Positive (N = 38)	Negative (N = 36)
myChoiceCDx			
Myriad			
Positive (N = 29)		29 (76.3%)	-
Negative (N = 45)		9 (23.7%)	36 (100%)

Table IV. Clinicopathological characteristics of HRD discordant cases.

	GIS score Myriad	GSS score Amoy	Histotype	Age at diagnosis	Family history	FIGO stage	Surgery	Residual tumor	NACT
1	22	58.2	HGSOC	40-45	No	IIIC	IDS	Yes *	Yes
2	29	51.7	HGSOC	65-70	Yes	IVB	PCS	No	No
3	14	84.8	HGSOC	55-60	No	IIIC	IDS	No	Yes
4	40	85.1	HGSOC	55-60	No	IVB	PCS	Yes *	No
5	32	64.1	HGSOC	50-55	No	IVB	PCS	No	No
6	22	52.9	HGSOC	65-70	Yes	IIIC	PCS	No	No
7	23	56.1	HGSOC	60-65	No	IIIC	PCS	No	No
8	23	90.4	HGSOC	60-65	Yes	IIIC	IDS	Yes *	Yes
9	39	62.5	HGSOC	65-70	Yes	IIIC	IDS	No	Yes

* ≤ 0.5 cm.

HGSOC: High grade serous carcinoma; IDS: interval debulking surgery; PCS: primary cytoreductive surgery; NACT = neoadjuvant chemotherapy.

es. The successful rate of HRD Focus assay in our cohort reached 84.2%. (Fig. 1). The Myriad MyChoiceCDx HRD evaluation was successfully performed in 89 of 95 cases (93.7%), and in the remaining 6 cases (surgical specimens) the analysis resulted inconclusive. The median turnaround time (TAT) from the test request to the available report was 7 days (range 5-9 days) for AmoyDx HRD Focus panel and 18 days (range 17-25 days) for Myriad MyChoiceCDx.

AmoyDx HRD Focus panel identified 38 (47.5%) HRD positive and 42 (52.5%) HRD negative tumors. HRD positive cases had a significant lower age at diagnosis, whereas no other significantly correlation with clinicopathological features was observed (Tab. II).

AMOYDX HRD FOCUS PANEL PERFORMANCE: COMPARISON WITH MYRIAD MYCHOICECDX RESULTS

The comparison between AmoyDx HRD focus panel and Myriad MyChoice results was performed including 74 cases which were successfully analyzed with both assays.

AmoyDx and Myriad assays focused on BRCA status assessment along with HRD evaluation. BRCA pathogenic mutations were found in 5 cases with both the assays. Complete concordance was achieved in 72 (97.3%) samples, including 68 BRCA negative and 4 BRCA positive (pathogenic mutation) tumors, whereas 2 (2.7%) samples reported a discordant results. In one case a somatic *BRCA1* large deletion from exon 14 to exon 18 was identified by Myriad assay only and another sample carried an alteration classified as pathogenic for AmoyDx test and VUS (Variant of Uncertain Significance) for Myriad evaluation (*BRCA2* variant in exon11:c.4284_4285insT; p.Q1429Sfs*9).

Regarding HRD status, the overall percent agreement (OPA) between AmoyDx and Myriad was 87.8% (65 of 74 tumours tested) (Tab. III and Fig. 2). In detail, using AmoyDx assay, all the negative cases (36 of 36




Figure 2. Comparison between HRD score: GSS AmoyDx (cut-off 50) and GSI Myriad (cut-off 42).

tumors, 100%) were confirmed as negative by Myriad whereas among 38 cases identified as HRD positive by AmoyDx, 29 (76.3%) tumors resulted positive and 9 (23.7%) negative by Myriad. The positive predictive value (PPV) of AmoyDX test was 83.3% and the negative predictive value (NPV) was 100%. The clinicopathological characteristics of the discordant cases are reported in Table IV.

Discussion

In the last years, the clinical management of women affected by ovarian cancers has been through a rapid evolution, prompted by progress in precision medicine. The recently introduced HRD assessment beyond BRCA1/2 status as a clinically relevant biomarker for therapeutic indications, poses a major challenge in hospital workflow as the gold standard assay for HRD evaluation. Myriad MyChoiceCDx is a centrally performed and costly assay, with no reimbursement scheduled, at least in Italy.

In this report, we describe our experience in with

the HRD Focus AmoyDx (CE-IVD) in our diagnostic workflow, focusing on the feasibility and reliability of in-house HRD-testing. To our knowledge, this is one of the firsts report of feasibility of HRD-testing in a real-life diagnostic setting, evaluating a consecutive series of advanced carcinoma who may change their treatment indications. We observed a successful rate of 84.2%, with failures due to low extracted DNA yield, mainly related to small biopsies or DNA quality sub-optimal, linked to formalin treatment and preanalytical condition that determined DNA deamination and fragmentation. Notably, the AmoyDx median TAT from the test request to the available report was 7 days, which was significantly shorter than the Myriad TAT of 18 days, the latter is also effected by logistic handling and transportation. Considering the clinical need to schedule the most effective therapy for the single patient in a short timeframe, both the successful rate and the TAT are crucial parameters to be taken under consideration to establish the clinical utility of an assay.

Applying the HRD Focus panel, we identified 47.5% HRD positive tumors, in line with the incidence reported in the PAOLA1 (48%)⁷, PRIMA (50.9%)⁶ and

VELIA (50.1%)⁸ trials. All tumors were evaluated with the gold standard Myriad MyChoiceCDx, obtaining an OPA of 87.8%. Our data were in accordance with the recent findings of Weichert and colleagues¹⁸ that reported an OPA of 81.6% between AmoyDX and Myriad assays in HRD assessment.

Recently, other HRD assays (i.e., OncoPrint Comprehensive Assay Plus, ThermoFisher Scientific or DDM HRD Solution, SOPHiA Genetics) have been placed on the market, aiming to provide HRD testing in diagnostic laboratories equipped with high throughput NGS systems. Moreover, great efforts have been made by European academic centers to develop a reliable and in-house feasible HRD test to replicate the Myriad MyChoiceCDx results¹⁹. Exciting results have been recently reached by the Leuven HRD testing, a targeted next generation sequencing - capture based investigating about 90,000 genome wide SNPs and HRR involved genes running on Illumina NovaSeq instrument. This test has an OPA with Myriad MyChoice PLUS of 91%, based on the analysis of 468 samples from the PAOLA-1 study and remarkably showed a similar impact of olaparib on progression free survival as Myriad test²⁰. These very promising results may pave the way to the introduction of in-house academic-developed HRD testing, even if some criticisms have to be addressed, including the requirement of powerful NGS instruments and the need to obtain the European Certification required for in vitro diagnostic use (CE-IVD mark).

Our study presents some limitations. This is a feasibility study and the results obtained should be considered preliminary and need to be confirmed in a larger cohort. Moreover, most of the patients in this population are still undergoing adjuvant treatment and are waiting to start maintenance treatment. Maintenance treatment and follow-up are fundamental parameters, especially in AmoyDx-Myriad discordant cases, to assess the utility of the AmoyDx HRD test in predicting clinical outcomes or likely magnitude of benefit from PARPis.

In conclusion, we report on HRD assessment using the HRD Focus AmoyDx (CE-IVD) in a real-life diagnostic setting. The major limitation we faced was the DNA yield required in the HRD Focus test, which lowered the success rate. However, the turnaround time compatible with clinical needs and the high concordance with the gold standard Myriad MyChoice CDx assay suggest the feasibility and reliability of HRD testing in diagnostic laboratories.

ACKNOWLEDGEMENTS

We acknowledge the laboratory technicians of the Division of Pathology (European Institute of Oncology

IRCCS, Milan, Italy) for sample collection and processing.

CONFLICT OF INTEREST

NC has received honoraria for consulting from Roche (ongoing), PharmaMar (ended), AstraZeneca (ongoing), Tesaro/GSK (ended), Immunogen (ongoing), Pfizer (ended), Clovis Oncology (ongoing), Merck Sharp & Dohme Corp. (ongoing), BIOCAD (ended), Mersana (ended), Eisai (ongoing), Oncxerna (ended); for speakers' bureau(s) from Clovis (ongoing), Novartis (ended), AstraZeneca (ongoing), Tesaro (ended), Merck Sharp & Dohme Corp. (ongoing), GSK (ongoing), Eisai (ongoing); grant/research support from AstraZeneca (ended), PharmaMar (ended), Roche (ended) and its Member Steering Committee ESMO Clinical Guidelines (ongoing) and Chair Scientific Committee ACTO Scientific onlus (ongoing). EG-R has received honoraria and/or advisory fees and/or research funding from AstraZeneca, Exact Sciences, Novartis, Roche, and ThermoFisher. MB has received honoraria for consulting, advisory role, speakers' bureau, travel, accommodation, expenses from MSD Oncology, Roche/Genetech, AstraZeneca, ThermoFisher Scientific and Illumina.

FUNDING

This work was partially supported by the Italian Ministry of Health with "RicercaCorrente", "5 × 1000".

ETHICAL CONSIDERATION

All information regarding human material was managed using anonymous numerical codes, and all samples were handled in compliance with the Helsinki Declaration. The study received the European Institute Review Board approval: UID 2386. Informed consent was obtained from all subjects involved in the study.

AUTHOR CONTRIBUTIONS

Conceptualization: CF, IB, MB, and EGR. Methodology: CF, and IB. Data collection: A.Ranghiero., IB, A.Rappa, GB, DV. Statistical analyses: CF. Writing-original draft: CF, IB, and MB. Writing-review and editing: CF, A.Ranghiero, IB, EGR, GB, A.Rappa, DV, MB. All authors have read and agreed to the published version of the manuscript.

References

- 1 Global Burden of Disease 2019 Cancer Collaboration; Kocarnik JM, Compton K, Dean FE, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 Cancer Groups From 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *JAMA Oncol* 2022;8:420-444. <https://doi.org/10.1001/jamaoncol.2021.6987>

- ² I numeri del cancro in Italia 2021 – https://www.aiom.it/wp-content/uploads/2021/10/2021_NumeriCancro_web.pdf
- ³ Lisio MA, Fu L, Goyeneche A, et al. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. *Int J Mol Sci* 2019;20:952. <https://doi.org/10.3390/ijms20040952>
- ⁴ Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2021;22:1721-1731. [https://doi.org/10.1016/S1470-2045\(21\)00531-3](https://doi.org/10.1016/S1470-2045(21)00531-3)
- ⁵ Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. *N Engl J Med* 2019;381:2403-2415. <https://doi.org/10.1056/NEJMoa1909707>
- ⁶ González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med* 2019;381:2391-2402. <https://doi.org/10.1056/NEJMoa1910962>
- ⁷ Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med* 2019;381:2416-2428. <https://doi.org/10.1056/NEJMoa1911361>
- ⁸ Swisher EM, Aghajanian C, O'Malley DM, et al. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. *Gynecol Oncol* 2022;164:245-253. <https://doi.org/10.1016/j.ygyno.2021.12.003>
- ⁹ FDA Lynparza: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf (accessed on 10 May 2022)
- ¹⁰ EMA Lynparza: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-35-ii-36_en.pdf (accessed on 10 May 2022)
- ¹¹ AIFA Lynparza: https://www.aifa.gov.it/documents/20142/961234/Determina_194-2022_Lynparza.pdf (accessed on 10 May 2022)
- ¹² Vergote I, González-Martín A, Ray-Coquard I, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. *Ann Oncol* 2022;33:276-287. <https://doi.org/10.1016/j.annonc.2021.11.013>
- ¹³ Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. *Cancer Discov* 2015;11:1137-1154. <https://doi.org/10.1158/2159-8290.Cd-15-071>
- ¹⁴ Wagener-Rydzek S, Merkelbach-Bruse S, Siemanowski J. Biomarkers for homologous recombination deficiency in cancer. *J Pers Med* 2021;11:612. doi:10.3390/jpm11070612
- ¹⁵ Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377-381. <https://doi.org/10.1016/j.jbi.2008.08.010>
- ¹⁶ AmoyDiagnostics. Available online: http://www.amoydiagnostics.com/productDetail_46.html
- ¹⁷ Fumagalli C, Betella I, Rappa A, et al. Tumor BRCA Testing in epithelial ovarian cancers: past and future-five-years' single-institution experience of 762 consecutive patients. *Cancers* 2022;14:1638. <https://doi.org/10.3390/cancers14071638>
- ¹⁸ Weichert W, Lukashchuk N, Yarinin A, et al. An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer *Int J Gynecol Cancer* 2021;31:A366.
- ¹⁹ Pujade-Lauraine E, Christinat Y, D'incalci M, et al. 201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative. *Int J Gynecol Cancer* 2021;31:A208.
- ²⁰ SGO 2022 Annual Meeting| March 18-21, 2022 <https://sgomtg22.us2.pathable.com/meetings/virtual/nRerYfh2bMwvczGuJ>